Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01558
|
|||||
| Drug Name |
Nonactin
|
|||||
| Synonyms |
nonactin; Werramycin-A; Antibiotic from Actinomycete; Upjohn 170t (high melting); UPJOHN 170T, high melting; UNII-TTP24WX8P7; 5342 PFW 19; TA-25-M-I; EINECS 229-911-3; A 4426; NSC 56409; E-79-C; NSC 52141; N-329-A; BRN 0076434; TTP24WX8P7; CHEBI:7614; GNF-PF-1094; 3584-A; NSC52141; 4,13,22,31,37,38,39,40-Octaoxapentacyclo(32.2.1.1(sup 7,10).1(sup 16,19).1(sup 25,28))tetracontane-3,12,21,30-tetrone, 2,5,11,14,20,23,29,32-octamethyl-, (1R-(1R*,2R*,5R*,7R*,10S*,11S*,14S*,16S*,19R*,20R*,23R*,25R*,28S*,29S*,32S*,34S*))-
|
|||||
| Indication | Cancer [ICD11: 2A00-2F9Z] | Preclinical | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C40H64O12
|
|||||
| Canonical SMILES |
CC1CC2CCC(O2)C(C(=O)OC(CC3CCC(O3)C(C(=O)OC(CC4CCC(O4)C(C(=O)OC(CC5CCC(O5)C(C(=O)O1)C)C)C)C)C)C)C
|
|||||
| InChI |
InChI=1S/C40H64O12/c1-21-17-29-9-13-34(49-29)26(6)38(42)46-23(3)19-31-11-15-36(51-31)28(8)40(44)48-24(4)20-32-12-16-35(52-32)27(7)39(43)47-22(2)18-30-10-14-33(50-30)25(5)37(41)45-21/h21-36H,9-20H2,1-8H3/t21-,22+,23+,24-,25-,26+,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-
|
|||||
| InChIKey |
RMIXHJPMNBXMBU-QIIXEHPYSA-N
|
|||||
| CAS Number |
CAS 6833-84-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 736.9 | Topological Polar Surface Area | 142 | ||
| Heavy Atom Count | 52 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 12 | |||
| XLogP |
6.6
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:7614
|
|||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (TTP24WX8P7) | |||||
| 2 | Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.